ReviewArthritis research & therapy2012
Progress in treatment of ANCA-associated vasculitis.
Review in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 63 citations in OpenAlex.
- BVAS version 3 and BVAS/GPA: standing on the same line?Clinical rheumatology · 2022Article
- Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives.Journal of clinical medicine · 2021Review
- Clinical characteristics and outcomes in microscopic polyangiitis patients with renal involvement: a study of 124 Chinese patients.BMC nephrology · 2019Observational
- Treatment Strategies in ANCA-Associated Vasculitis.Current rheumatology reports · 2019Review
- Lower cranial nerve palsy during radiotherapy for glottic cancer in a patient with Wegener's granulomatosis: An interesting case report.Molecular and clinical oncology · 2019Article
- Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.Clinical kidney journal · 2017Article
- B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.Arthritis research & therapy · 2017Observational
- Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.International urology and nephrology · 2017Review
- Updates in ANCA-associated vasculitis.European journal of rheumatology · 2016Review
- Fatal pulmonary complication during induction therapy in a patient with ANCA-associated vasculitis.Acta medica Lituanic · 2016Article
- Vasculitides and the Complement System: a Comprehensive Review.Clinical reviews in allergy & immunology · 2015Review
- Microscopic polyangiitis associated with pulmonary fibrosis.Clinical rheumatology · 2015Article
- Forme Fruste of HLH (haemophagocytic lymphohistiocytosis): diagnostic and therapeutic challenges.BMJ case reports · 2015Article
- Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers.Blood · 2014Article
- Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
- Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis.Arthritis research & therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies to neutrophil cytoplasmic antigen-associated vasculitis (AAV) is characterised by inflammation of blood vessels. The introduction of immunosuppressive therapy with glucocorticoids and cyclophosphamide transformed AAV from a fatal condition to a largely treatable condition. Over the past 30 years, considerable progress has been made refining immunosuppressive regimens with a focus on minimising toxicity. There is, however, a high unmet need in the treatment of AAV. A proportion of patients are refractory to current therapies; 50% experience a relapse within 5 years and treatment toxicity contributes to mortality and chronic disability. As knowledge of the pathogenesis of vasculitis grows, it is mirrored by the availability of biological agents, which herald a revolution in the treatment of vasculitis. Lymphocyte-targeted and cytokine-targeted agents have been evaluated for the treatment of AAV and are entering the routine therapeutic arena with the potential to improve patient outcomes. As rare diseases, treatment advances in vasculitis depend on international collaborative research networks both to establish an evidence base for newer agents and to develop recommendations for patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.